BENEVICH ERIC — SEC Form 4 filings
SEC reporting owner CIK 1643653. 18 Form 4 filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2024-02-02 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 16 legs across 11 filings — 186,848 shares, $25,618,318 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 51.
- Largest priced transaction: sale of 69,521 shares @ $139.38 ($9,689,761) in NEUROCRINE BIOSCIENCES INC, filed 2024-03-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | Chief Commercial Officer | 15 | — | 16 legs · 186,848 sh · $25,618,318 | 48 |
| aTYR PHARMA INC (ATYR) | Director | 3 | — | — | 3 |
Form 4 filings — BENEVICH ERIC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Grant/award (A): 6,275 @ $0 · Tax withholding (F): 3,386 @ $156.22 | EDGAR |
| 2026-09-10 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 3,194 @ $43.24 · Sale (S): 2,154 @ $154.61 · Option exercise (M): 3,194 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,005 @ $0 · Tax withholding (F): 1,082 @ $123.10 · Option exercise (M): 1,961 @ $0 · Tax withholding (F): 1,058 @ $124.12 · Option exercise (M): 2,083 @ $0 · Tax withholding (F): 1,124 @ $124.12 · +7 more | EDGAR |
| 2026-02-03 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,294 @ $0 · Tax withholding (F): 1,292 @ $136.06 · Option exercise (M): 2,294 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4/A | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 12,830 @ $35.99 · Option exercise (M): 12,830 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,970 @ $35.99 · Sale (S): 5,970 @ $151.74 · Option exercise (M): 5,970 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-14 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,083 @ $0 · Sale (S): 1,098 @ $116.74 · Option exercise (M): 1,961 @ $0 · Sale (S): 1,056 @ $116.71 · Grant/award (A): 42,805 (derivative) @ $0 · Grant/award (A): 8,022 (derivative) @ $0 · +2 more | EDGAR |
| 2025-02-12 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 1,860 @ $0 · Sale (S): 980 @ $118.31 · Option exercise (M): 1,860 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 2,294 @ $0 · Sale (S): 1,207 @ $152.94 · Option exercise (M): 2,294 (derivative) @ $0 | EDGAR |
| 2024-12-12 | 4 | aTYR PHARMA INC (ATYR) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 7,231 @ $81.49 · Sale (S): 7,231 @ $133.36 · Option exercise (M): 12,587 @ $81.05 · Sale (S): 12,587 @ $133.36 · Option exercise (M): 7,231 (derivative) @ $81.49 · Option exercise (M): 12,587 (derivative) @ $81.05 | EDGAR |
| 2024-03-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 5,479 @ $79.02 · Sale (S): 5,479 @ $139.38 · Option exercise (M): 69,521 @ $81.05 · Sale (S): 69,521 @ $139.38 · Option exercise (M): 5,479 (derivative) @ $79.02 · Option exercise (M): 69,521 (derivative) @ $81.05 | EDGAR |
| 2024-02-29 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Option exercise (M): 53,143 @ $43.24 · Sale (S): 53,143 @ $134.69 · Option exercise (M): 21,857 @ $79.02 · Sale (S): 21,857 @ $134.69 · Option exercise (M): 53,143 (derivative) @ $43.24 · Option exercise (M): 21,857 (derivative) @ $79.02 | EDGAR |
| 2024-02-15 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,098 @ $133.01 · Grant/award (A): 39,426 (derivative) @ $0 · Grant/award (A): 7,846 (derivative) @ $0 | EDGAR |
| 2024-02-08 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,280 @ $142.12 · Sale (S): 980 @ $134.19 | EDGAR |
| 2024-02-02 | 4 | NEUROCRINE BIOSCIENCES INC (NBIX) | Sale (S): 1,207 @ $140.78 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1643653 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →